Study to Evaluate Adverse Events, Change in Disease Activity, & How Oral

Status Recruiting

Clinical Trial Summary

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: third line or later of treatment (3L) + chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101 and a dose expansion phase to determine the change in disease activity in participants with CLL or non-GCB DLBCL. Approximately 128 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide. In the Dose Escalation phase of the study participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 60 month study duration. In the dose expansion phase of the study participants receive oral ABBV-101, as part of the approximately 60 month study duration . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05753501
Study type	Interventional
Source	AbbVie
Contact	ABBVIE CALL CENTER
Phone	844-663-3742
Email	abbvieclinicaltrials@abbvie.com
Status	Recruiting
Phase	Phase 1
Start date	June 9, 2023
Completion date	April 11, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04966156` - Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT	N/A
Recruiting	`NCT05942885` - Hypnosis: a Path to Appeasement	N/A
Recruiting	`NCT05715047` - Intervention for Fatigue in HCT Recipients	N/A
Recruiting	`NCT05142033` - Avera Cancer Sequencing and Analytics Protocol (ASAP)
Completed	`NCT06053918` - Research-Action in Hematology From Hospitalization to Home
Recruiting	`NCT05175508` - Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS	Phase 2/Phase 3
Not yet recruiting	`NCT04822974` - TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS	N/A
Not yet recruiting	`NCT06279585` - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD	N/A
Recruiting	`NCT05481502` - An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors	N/A
Not yet recruiting	`NCT04412135` - The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Not yet recruiting	`NCT06377059` - Early Detection of Complications During Immunotherapy for Haematological Malignancy	N/A
Completed	`NCT04235153` - CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
Recruiting	`NCT05626764` - QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
Active, not recruiting	`NCT04035447` - Symptom Management for YA Cancer Survivors	N/A
Not yet recruiting	`NCT05602168` - Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance	N/A
Terminated	`NCT03955276` - An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
Recruiting	`NCT03091933` - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)	Phase 1/Phase 2
Withdrawn	`NCT01792882` - Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
Active, not recruiting	`NCT05493800` - Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT	Phase 2
Active, not recruiting	`NCT05690230` - Improving Patient Experience: BMBA	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms